Biomarkers, Not DSM, Needed To Speed Dx, Drug Development For Brain Disorders
This article was originally published in The Gray Sheet
Executive Summary
Diagnosing and treating brain disorders relies too much on subjective factors. But there are efforts brewing to turn that approach on its head, and move towards better biomarker-based diagnostics, says the Broad Institute’s Steven Hyman, former head of the National Institute of Mental Health.
You may also be interested in...
Research In Brief
Imaging self-referral scrutiny
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.